Optimi Health (OPTH) said Monday it has secured supplies of naturally derived ibogaine and will begin developing finished drug products this summer at its facility in British Columbia.
The company plans to produce 50mg and 100mg ibogaine capsules and establish manufacturing, testing, packaging, and labeling processes.
CEO Dane Stevens said interest in ibogaine research is increasing, citing a $50 million Texas program supporting the treatment's development.
Optimi said a recent US executive order identified ibogaine among psychedelic therapies targeted for accelerated FDA review and expanded patient access.
Ibogaine is being studied for opioid use disorder, PTSD, and traumatic brain injury.
Optimi shares rose 20% in Monday trading.
Price: $5.55, Change: $+0.91, Percent Change: +19.50%